TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cellsA mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressorsA fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoNanocrystal targeting in vivo.Bit1 in anoikis resistance and tumor metastasisAnastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursorsCrystal structure of a human peptidyl-tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activityMetadherin, a cell surface protein in breast tumors that mediates lung metastasisThe anti-angiogenic peptide anginex disrupts the cell membrane.Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment.Biomimetic amplification of nanoparticle homing to tumorsDynamic imaging of arginine-rich heart-targeted vehicles in a mouse model.Quantity and accessibility for specific targeting of receptors in tumours.Molecular profiling of heart endothelial cells.Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds.Drug targeting to specific vascular sites.Specialization of tumour vasculature.Selection of phage-displayed peptides on live adherent cells in microfluidic channels.Targeting the prostate for destruction through a vascular address.Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature.Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cellsA tumor-homing peptide with a targeting specificity related to lymphatic vessels.Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.Drug identification through in vivo screening of chemical libraries.Lymphatic zip codes in premalignant lesions and tumors.Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptidesTargeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display.Trophoblast cell activation by trophinin ligation is implicated in human embryo implantationMolecular changes in the vasculature of injured tissuesIn vivo tumor cell targeting with "click" nanoparticles.Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin.C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.Cooperative nanomaterial system to sensitize, target, and treat tumors.Targeting of albumin-embedded paclitaxel nanoparticles to tumors.New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation.Targeting of drugs and nanoparticles to tumors.Angiostatic peptides use plasma fibronectin to home to angiogenic vasculaturePlasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion
P50
Q24298072-754BCAA5-C727-4C57-9796-1196A6380F95Q24314955-C54B9F57-94CA-4B93-BA38-6E47C70E40CAQ24530544-E0BC23AE-B90E-4900-9D2C-AF4890ED83B2Q24538147-086C4D35-00B3-4691-B1AE-BD3874024C26Q26995189-4325A05C-17B6-404B-9A67-33C36A468204Q27641924-93ACEE85-3CB2-45A0-9F16-E66C09C58CB8Q27642732-0A2AD830-76C8-41FB-83C3-F5942C1AC465Q28257184-9915B28D-722E-42B4-8EA7-674808B5FCB5Q30159968-C6A674B7-F3D9-4907-98EC-3C7AE2294358Q30379645-2F0422D5-C337-4762-BF3C-E651A336AB1CQ30478897-C67ABECD-3A10-4AD2-8F84-400DDE57E915Q30482759-2748770B-3CC2-48EF-99CE-D52C5A2A933FQ30580276-5CA56B3B-8818-4497-8C72-859F39FDDF7DQ30797700-D7659CF8-6ED0-451F-94B7-E5759BA7AFC3Q30807745-403D7A17-E081-4E3B-96EE-2491EC52D1BEQ30883393-6C78E842-568D-4539-AFC7-15368CE04D60Q30896811-0496AB77-2FD0-4A1C-B420-A45AC8783607Q31004986-49310E53-79CD-4F3F-8A66-8634DA10E4E4Q31037658-D4E1D619-543D-4D8C-9D73-9E8FFE5EC863Q31039259-80864FC3-8DFC-4B4D-99A4-8C9E8798ABBAQ31079430-F6FD91DE-3D9E-4CC1-A5E6-EAC1556E70D3Q32127308-7F82B78F-9D95-4FE4-B338-39D9E64B72A7Q33195813-B17DCB4D-899A-432A-85B7-83E7065D87DFQ33195814-EE4C89D4-8281-4884-AB17-F547AF55F058Q33203372-E13AAAD8-6568-4C1D-AEA3-7FDA06A90533Q33245440-825599B3-4A9A-4C40-9967-41C569700C9DQ33246815-EAB603AA-ED08-42F9-AF3F-E364DABA861BQ33270631-2551DF54-EB99-48DA-B85B-7788BADBF237Q33278668-D3342193-746B-4FCE-A889-EC92F38194E3Q33289271-0C3A1DCE-506F-4A9E-89B8-1BF094F1ABADQ33350022-2812E35A-DC8B-4E51-A74E-B46677AD12D3Q33417922-C4AF4470-8258-4464-9C16-E47EC025D80BQ33508760-1B48D74C-1D6E-4FC2-A8FD-1E8006498854Q33524689-1084B76D-0E41-4A0A-B1EE-2BFA8A7DAEE4Q33667994-642C33A2-7BE7-452E-96DC-41CBAF65E099Q33694228-6626533B-4E42-40C6-844F-41E2B427E8A2Q33705060-482B7FBF-0477-4D4B-860C-C8C5C9185395Q33751710-098FF459-D3AB-48B8-B760-BE94DAECDE13Q33837087-5285CDA5-FDB0-484B-A01B-9D0521C67199Q33892041-2FBB0B83-E33E-495E-8AA6-DD8CF16C5747
P50
description
American medical researcher
@en
Amerikaans arts
@nl
dokter asal Amerika Serikat
@id
finnisch-US-amerikanischer Zellbiologe und Krebsforscher
@de
name
Erkki Ruoslahti
@ast
Erkki Ruoslahti
@ca
Erkki Ruoslahti
@da
Erkki Ruoslahti
@de
Erkki Ruoslahti
@en
Erkki Ruoslahti
@es
Erkki Ruoslahti
@fi
Erkki Ruoslahti
@fr
Erkki Ruoslahti
@hu
Erkki Ruoslahti
@it
type
label
Erkki Ruoslahti
@ast
Erkki Ruoslahti
@ca
Erkki Ruoslahti
@da
Erkki Ruoslahti
@de
Erkki Ruoslahti
@en
Erkki Ruoslahti
@es
Erkki Ruoslahti
@fi
Erkki Ruoslahti
@fr
Erkki Ruoslahti
@hu
Erkki Ruoslahti
@it
altLabel
Ruoslahti
@de
prefLabel
Erkki Ruoslahti
@ast
Erkki Ruoslahti
@ca
Erkki Ruoslahti
@da
Erkki Ruoslahti
@de
Erkki Ruoslahti
@en
Erkki Ruoslahti
@es
Erkki Ruoslahti
@fi
Erkki Ruoslahti
@fr
Erkki Ruoslahti
@hu
Erkki Ruoslahti
@it
P166
P1006
P214
P244
P269
P5587
P646
P906
P1006
P106
P1412
P166
P19
P21
P213
0000 0001 0985 8191
P214
P244
nr95011795